Review Article
Article
Below are the latest Acta Pharmacologica Sinica articles published online ahead of print publication.
Currently no content available!
- Home /
- Home
Acta Pharmacologica Sinica招聘科学编辑
Acta Pharmacologica Sinica（《中国药理学报》）是由中国药理学会和中国科学院上海药物研究所主办，中国科协主管的英文学术期刊。因工作需要，现招聘全职科学编辑1名，具体要求如下：
- 岗位职责：
- 负责日常稿件的按时评估和编辑加工
- 参加学术会议，拜访有关专家和实验室，挖掘优质稿源
- 参与专题策划和落实
- 参与宣传和推广，如期刊微信公众号和网络传播
Importance of integrating nanotechnology with pharmacology and physiology for innovative drug delivery and therapy – an illustration with firsthand examples
Nanotechnology has been applied extensively in drug delivery to improve the therapeutic outcomes of various diseases. Tremendous efforts have been focused on the development of novel nanoparticles and delineation of the physicochemical properties of nanoparticles in relation to their biological fate and functions. However, in the design and evaluation of these nanotechnology-based drug delivery systems, ...
Discovery and development of NA-1 for the treatment of acute ischemic stroke
Stroke creates a complex interplay of multiple signaing pathways including excitotoxicity, ionic imbalance, inflammation, oxidative stress and apoptosis. There are very few treatments that have been shown to be beneficial in acute stroke. Recent findings have provided insights into the pathophysiology and mechanisms of ischemic stroke, complementing the traditional glutamate hypothesis: the molecular interaction between PSD95 and GluN2B has been identified as a culprit in stroke-mediated excitotoxicity, leading to the discovery of NA-1, a peptide that disrupts that interaction, as a potent neuroprotective agent for the treatment of acute stroke. ...
Therapeutic gene editing: delivery and regulatory perspectives
Gene-editing technology is an emerging therapeutic modality for manipulating the eukaryotic genome by using target-sequence- speci c engineered nucleases. Because of the exceptional advantages that gene-editing technology offers in facilitating the accurate correction of sequences in a genome, gene editing-based therapy is being aggressively developed as a next-generation therapeutic approach to treat a wide range of diseases.
Defining the minimum substrate and charge recognition model of gamma-secretase
γ-Secretase is an intramembrane aspartyl protease that cleaves the C99 fragment of amyloid precursor protein to generate extracellular Aβ peptides. These peptides can oligomerize and aggregate to form amyloid plaques, processes that are widely believed to be causal for Alzheimer’s disease. In spite of this critical function, it remains unknown how γ-secretase recognizes C99 and its other substrates, including Notch.
Insights into molecular therapy of glioma: current challenges and next generation blueprint
Glioma accounts for the majority of human brain tumors. With prevailing treatment regimens, the patients have poor survival rates. In spite of current development in mainstream glioma therapy, a cure for glioma appears to be out of reach. The infiltrative nature of glioma and acquired resistance substancially restrict the therapeutic options. Better elucidation of the complicated pathobiology of glioma and proteogenomic characterization might eventually open novel avenues for the design of more sophisticated and effective combination regimens.
Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier
To achieve synergistic therapeutic ef cacy and prevent cancer relapse, chemotherapy and immunotherapy have been combined asa new modality for tumor treatment. In this work, we designed a redox-responsive immunostimulatory polymeric prodrug carrier, PSSN10, for programmable co-delivery of an immune checkpoint inhibitor NLG919 (NLG) and a chemotherapeutic doxorubicin (DOX).
CN 31-1347/R
ISSN 1671-4083
EISSN 1745-7254
2017 Impact Factor 3.562*
53/171 Chemistry, Multidisciplinary
63/261 Pharmacology & Pharmacy
Jian Ding
*2018 Journal Citation Reports® Science Edition
Society Resources
Publishing Information
Acta Pharmacologica Sinica is published by SPRINGER NATURE
Membership
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics.
